Zhongshan Health Technology Park Development Co Ltd and QuaCell Biotechnology Co Ltd on August 23 signed an investment agreement, and the QuaCell-Sartorius CDMO Platform project (Contract Development and Manufacturing Organization) was officially implanted at the National Health Technology Park.

The QuaCell-Sartorius CDMO project plans to build the first domestic CDMO platform for biopharmaceuticals based on the QbD (Quality by Design) concept, providing a full range of QbD-based protein pharmaceutical production process development, process characterization and production outsourcing services to Chinese and global customers.

The total investment of this project stands at 200 million yuan, for construction including a QbD research and development center, two GMP protein biopharmaceuticals production lines and one McAb preparation production line.

In 2018, during the 13th Zhongshan Forum for Health and Development, German company Sartorius and QuaCell signed a cooperation agreement to jointly build a laboratory. Both parties will invest in the construction of a biopharmaceutical CDMO outsourcing service center based on the QbD concept. QuaCell's subsidiary team will be the operation team of the center, responsible for process development technical services and production services as well as the daily operation management of the project. As the supplier of QbD research and development equipment, Sartorius will provide corresponding production equipment and technical support through the QbD experimental center.